Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859291 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3868197 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3863209 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL313504 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL1475879 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL61256 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9209758 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9681594 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL8669383 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3856545 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117128-A1 | INTRAOCULAR PRESSURE LOWERING AGENT, AND AGENT FOR TREATING OR PREVENTING GLAUCOMA OR OCULAR HYPERTENSION | ＳＡＮＳＨＯ株式会社 | 2024-06-06 | — | — | WO | disclosed |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | SANSHO CO. LTD. (JP) | 2024-04-11 | — | — | US | disclosed |
| EP-4252756-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | Sansho Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | OCHANOMIZU UNIVERSITY (JP) | 2023-04-06 | — | — | US | disclosed |
| US-10413559-B2 | Method for treating demyelinating disease | OCHANOMIZU UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-2949329-B1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | UNIV OCHANOMIZU (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2803359-B1 | THERAPEUTIC AGENT FOR JOINT DISEASES | SANSHO CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | OCHANOMIZU UNIVERSITY (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2949329-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | Ochanomizu University (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-9085593-B2 | Therapeutic agent for arthrosis | SANSHO CO., LTD. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20080234232-A1 | Methods and compositions for targeting AFAP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-25 | — | — | US | disclosed |
| EP-1402894-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVES | MUROFUSHI KIMIKO (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20060122155-A1 | Carbacyclic phosphatidic acid derivative | SANSHO CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1535926-A1 | CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVE | Murofushi, Kimiko (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040220149-A1 | Nerve cell survival promoters containing cyclic phosphatidic acid derivative | GENCOM CORPORATION (JP) | 2004-11-04 | — | — | US | disclosed |
| US-20040214799-A1 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives | MUROFUSHI, KIMIKO (JP) | 2004-10-28 | — | — | US | disclosed |
| US-20040176329-A1 | Drugs for promoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid | KIMIKO MUROFUSHI (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1402894-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVES | Gencom Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1391204-A1 | NERVE CELL SURVIVAL PROMOTERS CONTAINING CYCLIC PHOSPHATIDIC ACID DERIVATIVE | Gencom Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1386612-A1 | DRUGS FO RPROMOTING THE PROLIFERATION, DIFFERENTIATION AND/OR SURVIVAL OF GLIAL CELLS CONTAINING CYCLIC PHOSPHATIDIC ACID | Gencom Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | PHOSPHO1, SGMS1, PLD1 | PTPN7 2293/4885HMGCR 1411/4885RECQL 3592/4885 |
| US-20040214799-A1 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives | PTEN, PLCB1, PLCG2 | PTPN7 3114/4885HMGCR 1547/4885RECQL 4135/4885 |
| US-20040176329-A1 | Drugs for promoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid | GAP43, SMPD2, SMPD3 | PTPN7 2136/4885HMGCR 977/4885RECQL 3094/4885 |
| US-20080234232-A1 | Methods and compositions for targeting AFAP | ARPC5, ARPC2, ACTR2 | PTPN7 1800/4885HMGCR 3361/4885RECQL 2534/4885 |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | PMP22, MAG, SGMS1 | PTPN7 1215/4885HMGCR 2093/4885RECQL 3199/4885 |
| US-20060122155-A1 | Carbacyclic phosphatidic acid derivative | SGMS1, SGMS2, LPAR2 | PTPN7 2195/4885HMGCR 905/4885RECQL 4564/4885 |
| US-10413559-B2 | Method for treating demyelinating disease | PMP22, MAG, SGMS1 | PTPN7 1364/4885HMGCR 685/4885RECQL 2785/4885 |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | CCL11, ELANE, MMP1 | PTPN7 3368/4885HMGCR 1408/4885RECQL 4011/4885 |
| US-20040220149-A1 | Nerve cell survival promoters containing cyclic phosphatidic acid derivative | NGF, GAP43, PLA2G4A | PTPN7 2175/4885HMGCR 3234/4885RECQL 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.